Shamburg News · 8-K filed Nov 16, 2026, 8:00 AM EST
Relmada Therapeutics Appoints Jørn Skibsted Jakobsen as Chief Development Officer
RLMD · RELMADA THERAPEUTICS, INC.
- Leadership change
- Reg FD disclosure
- Materiality: medium
On November 16, 2026, Relmada Therapeutics, Inc. announced in a press release, furnished as Exhibit 99.1 under Item 7.01, the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development across the pipeline, including the planned Phase 3 SPECTRUM program for NDV-01. The filing does not state an effective date for the appointment.
Source: SEC EDGAR, Form 8-K, Item 7.01, accession 0001213900-26-120144.
Written from the filing by Shamburg Markets. Figures are as reported by the company.